CRISPR Therapeutics
CRSP
412 hedge funds and large institutions have $7.23B invested in CRISPR Therapeutics in 2020 Q4 according to their latest regulatory filings, with 139 funds opening new positions, 132 increasing their positions, 88 reducing their positions, and 35 closing their positions.
297% more first-time investments, than exits
New positions opened: 139 | Existing positions closed: 35
81% more capital invested
Capital invested by funds: $4B → $7.23B (+$3.23B)
50% more repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 88
33% more funds holding
Funds holding: 310 → 412 (+102)
6% more call options, than puts
Call options by funds: $294M | Put options by funds: $278M
1.93% less ownership
Funds ownership: 68.24% → 66.31% (-1.9%)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$231M |
| 2 |
Morgan Stanley
New York
|
+$26.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$26.8M |
| 4 |
Jane Street
New York
|
+$20.8M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$19.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$112M |
| 2 |
VVM
Versant Venture Management
San Francisco,
California
|
-$69.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$43.3M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$37.6M |
| 5 |
Renaissance Technologies
New York
|
-$28.5M |
CRSP Hedge Fund Activity: Q4 2020 in Review
412 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2020, worth a combined $7.23B — up 81% from $4B a quarter earlier.
Buyers outnumbered sellers: 139 funds opened new CRSP positions and 35 closed out — a net gain of 104 holders — while 132 added to existing stakes and 88 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $231M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $112M sold.
- 412 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2020, up from 310 in Q3 2020.
- Funds reported $7.23B of CRISPR Therapeutics stock for Q4 2020, up 81% quarter-over-quarter.
- 139 funds opened new CRISPR Therapeutics positions in Q4 2020 and 35 closed out, a net change of +104 holders.
- The largest CRISPR Therapeutics buyer in Q4 2020 was ARK Investment Management, an estimated $231M added.
- The largest CRISPR Therapeutics seller in Q4 2020 was Perceptive Advisors, an estimated $112M sold.
Based on aggregated 13F filings for Q4 2020.